Sunshine Heart (NASDAQ:CHFS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday. The firm currently has a $4.00 price target on the stock. Zacks Investment Research‘s target price would suggest a potential downside of 3.61% from the stock’s current price.

According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “

Separately, ValuEngine downgraded shares of Sunshine Heart from a “sell” rating to a “strong sell” rating in a research note on Monday, October 2nd.

Shares of Sunshine Heart (NASDAQ:CHFS) traded up $0.63 during trading hours on Monday, hitting $4.15. 3,567,443 shares of the stock traded hands, compared to its average volume of 1,090,000. The company has a market capitalization of $6.33, a P/E ratio of -0.03 and a beta of 2.25. Sunshine Heart has a 52-week low of $2.87 and a 52-week high of $220.60.

In other news, major shareholder Ki Yong Choi acquired 61,645 shares of the stock in a transaction dated Thursday, October 12th. The stock was purchased at an average cost of $0.52 per share, with a total value of $32,055.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Upgrades Sunshine Heart (CHFS) to Buy” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/zacks-investment-research-upgrades-sunshine-heart-chfs-to-buy/1798916.html.

Sunshine Heart Company Profile

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on Sunshine Heart (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with Analyst Ratings Network's FREE daily email newsletter.